Hybridize Therapeutics
Private Company
Total funding raised: $3.5M
Overview
Hybridize Therapeutics is a private, clinical-stage biotech developing kidney-targeted RNA therapeutics to address a major unmet need in nephrology. Its platform enables the design of chemically modified oligonucleotides with extended half-lives and cell-specific delivery, primarily targeting the proximal tubule epithelial cell (PTEC). The company's lead program, HYB_BKV, is a direct-acting antiviral for BK virus in transplant patients and has been partnered with AiCuris in a deal worth up to €100M, with the program now in Phase 1/2 clinical trials.
Technology Platform
Proprietary platform for developing kidney-targeted, chemically modified antisense oligonucleotides (ASOs) with extended half-life and specific delivery to proximal tubule epithelial cells (PTECs).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In the BK virus space, Hybridize's partnered program appears to be a first-in-class direct antiviral, competing against supportive care and immunosuppression reduction. In broader kidney disease, it will face competition from companies developing small molecules, antibodies, and other modalities for conditions like hyperphosphatemia (e.g., Amgen, Kyowa Kirin) and ADPKD (e.g., Otsuka, Reata). Its key differentiator is the focused RNA-targeting approach to a specific renal cell type.